SGLT2 inhibitors and peripheral vascular events: a review of the literature
E Marchiori, RN Rodionov, F Peters… - Heart Failure …, 2022 - heartfailure.theclinics.com
Cardiovascular disease (CVD) has many faces and continues to be the leading cause of
death globally. Besides well-known entities such as ischemic heart disease and stroke …
death globally. Besides well-known entities such as ischemic heart disease and stroke …
The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a …
NCC Werkman, JHM Driessen, CDA Stehouwer… - Cardiovascular …, 2023 - Springer
Background Numerous studies have investigated the potential association of sodium-
glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb …
glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb …
Safety of sodium-glucose transporter 2 (SGLT-2) inhibitors in patients with type 2 diabetes: a meta-analysis of cohort studies
CX Li, TT Liu, Q Zhang, Q Xie, XH Geng… - Frontiers in …, 2023 - frontiersin.org
Aims: This study aimed to investigate the association between the use of sodium-glucose
transporter 2 inhibitors (SGLT-2i) and the risk of diabetic ketoacidosis (DKA), lower limb …
transporter 2 inhibitors (SGLT-2i) and the risk of diabetic ketoacidosis (DKA), lower limb …
Effects of sodium‐glucose cotransporter type 2 inhibitors on cardiovascular, renal, and safety outcomes in patients with cardiovascular disease: a meta‐analysis of …
C Zheng, M Lin, Y Chen, H Xu, L Yan, H Dai - Cardiovascular Diabetology, 2021 - Springer
Background Controlled studies and observational studies have shown that sodium-glucose
cotransporter type 2 inhibitors (SGLT-2i) are beneficial for the survival of patients with heart …
cotransporter type 2 inhibitors (SGLT-2i) are beneficial for the survival of patients with heart …
[HTML][HTML] Initiation of SGLT2 inhibitors and the risk of lower extremity minor and major amputation in patients with type 2 diabetes and peripheral arterial disease: a …
RN Rodionov, F Peters, U Marschall, H L'Hoest… - European Journal of …, 2021 - Elsevier
Objective To assess the association between long term risk of hospitalisation for heart failure
(HHF) and lower extremity minor and major amputation (LEA) in patients initiating sodium …
(HHF) and lower extremity minor and major amputation (LEA) in patients initiating sodium …
Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review
N Skeik, SA Elejla, A Sethi, J Manunga… - Vascular …, 2023 - journals.sagepub.com
Peripheral artery disease (PAD) and diabetes mellitus are two overwhelming health
problems associated with major cardiovascular (CV) and limb events, in addition to …
problems associated with major cardiovascular (CV) and limb events, in addition to …
Comparison of the risk of SGLT2is and NonSGLT2is in leading to amputation: A network meta-analysis
M Qiu, LL Ding, M Zhang, HR Zhou - Journal of Diabetes and its …, 2021 - Elsevier
Objective Whether sodium-glucose cotransporter 2 inhibitors (SGLT2is) increase the risk of
amputation or not remains controversial. We aimed to evaluate the relative risk of different …
amputation or not remains controversial. We aimed to evaluate the relative risk of different …
Validation of the Histamine‐and Heat‐Induced Axon‐Reflex Flare Response in a Nonselected Population of People With Type 1 Diabetes
P Tind, A Larsen, MK Borbjerg, SL Vecchio… - Muscle & …, 2025 - Wiley Online Library
ABSTRACT Introduction/Aims Diabetic peripheral neuropathy affects small nerve fibers
early, but adequate evaluation has proven difficult. One method for functional assessment of …
early, but adequate evaluation has proven difficult. One method for functional assessment of …
Investigation of cardiorenal outcomes and incidence of genitourinary tract infection after combined SGLT2 inhibitor and ACEI/ARB use in patients with chronic kidney …
Background: Sodium‒glucose cotransporter-2 (SGLT2) inhibitors offer glycaemic and
cardiorenal benefits in the early stage of chronic kidney disease (CKD). However, the use of …
cardiorenal benefits in the early stage of chronic kidney disease (CKD). However, the use of …
[PDF][PDF] Η επίδραση των αντιδιαβητικών σκευασμάτων στους ακρωτηριασμούς σε διαβητικούς ασθενείς
ΣΔ Μανδάνας - 2023 - ir.lib.uth.gr
Περίληψη Η μελέτη CANVAS και η πιθανή συσχέτιση της καναγλιφλοζίνης με διπλάσιο
σχεδόν κίνδυνο ακρωτηριασμού κάτω άκρου σε διαβητικούς ασθενείς έθεσαν το ερώτημα της …
σχεδόν κίνδυνο ακρωτηριασμού κάτω άκρου σε διαβητικούς ασθενείς έθεσαν το ερώτημα της …